Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women

被引:15
作者
Gan, C. Q. [2 ]
Wang, X. Y. [2 ]
Cao, Y. D. [1 ]
Ye, W. X. [1 ]
Liu, H. [1 ]
Sun, Y. Y. [1 ]
机构
[1] Chongqing Med Univ, Pathol Lab, Chongqing, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Chongqing, Peoples R China
关键词
Polymorphism; CYP2C19; Breast cancer; Genetics; TAMOXIFEN; CYP2C9; INHIBITION; GENOTYPE; PROMOTES; SURVIVAL; ENZYMES;
D O I
10.4238/2011.December.5.3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytochrome P450 (CYP) 2C19 metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids, which significantly promote proliferation of cancer cells in vitro and in vivo. We looked for a possible association between human CYP2C19*3 gene polymorphism and breast cancer in the Chinese Han population. In a Chinese Han case-control study of breast cancer patients (N = 600) and age-and gender-matched healthy controls (N = 600), we investigated polymorphism in the CYP2C19 gene by PCR-RFLP analysis. The CYP2C19*3 AG + AA genotype was significantly more prevalent in breast cancer patients than in control subjects (6.67 vs 3.00%; P = 0.003). The odds ratio for carriers of AG + AA genotype for breast cancer was 2.31 (95% confidence interval = 1.27-4.43). Among patients, estrogen receptor, tumor size, histologic grade, presence of primary lymphonode metastases, progesterone receptor positivity, and age at diagnosis were not found to be significantly associated with CYP2C19*3 genotypes (all P > 0.05). We conclude that the CYP2C19*3 gene polymorphism is associated with breast cancer risk in Chinese Han women.
引用
收藏
页码:3514 / 3519
页数:6
相关论文
共 23 条
[1]   Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: Implications for predicting clinical drug interactions [J].
Dixit, Vaishali ;
Hariparsad, Niresh ;
Li, Fang ;
Desai, Pankaj ;
Thummel, Kenneth E. ;
Unadkat, Jashvant D. .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (10) :1853-1859
[2]   Does race modify the association between CYP1B1 Val432Leu polymorphism and breast cancer risk? A critical appraisal of a recent meta-analysis [J].
Economopoulos, Konstantinos P. ;
Sergentanis, Theodoros N. .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (01) :293-294
[3]   Influence of polymorphisms of drug metabolizing enzymes (CYP2136, CYP2C9, CYPX19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide [J].
Ekhart, Corine ;
Doodeman, Valerie D. ;
Rodenhuis, Sjoerd ;
Smits, Paul H. M. ;
Beijnen, Jos H. ;
Huitema, Alwin D. R. .
PHARMACOGENETICS AND GENOMICS, 2008, 18 (06) :515-523
[4]   Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis [J].
Ercan, B. ;
Ayaz, L. ;
Cicek, D. ;
Tamer, L. .
CELL BIOCHEMISTRY AND FUNCTION, 2008, 26 (03) :309-313
[5]   The V433M variant of the CYP4F2 is associated with ischemic stroke in male swedes beyond its effect on blood pressure [J].
Fava, Cristiano ;
Montagnana, Martina ;
Almgren, Peter ;
Rosberg, Lena ;
Lippi, Giuseppe ;
Hedblad, Bo ;
Engstroem, Gunnar ;
Berglund, Goeran ;
Minuz, Pietro ;
Melander, Olle .
HYPERTENSION, 2008, 52 (02) :373-380
[6]   Inhibition of cytochrome P4502C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease [J].
Fichtlscherer, S ;
Dimmeler, S ;
Breuer, S ;
Busse, R ;
Zeiher, AM ;
Fleming, I .
CIRCULATION, 2004, 109 (02) :178-183
[7]   14,15-EET analogs: characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries [J].
Gauthier, KM ;
Falck, JR ;
Reddy, LM ;
Campbell, WB .
PHARMACOLOGICAL RESEARCH, 2004, 49 (06) :515-524
[8]   Genetic Polymorphisms of CYP2D6*10 and CYP2C19*2,*3 Are Not Associated With Prognosis, Endometrial Thickness, or Bone Mineral Density in Japanese Breast Cancer Patients Treated With Adjuvant Tamoxifen [J].
Goetz, Matthew ;
Suman, Vera .
CANCER, 2010, 116 (04) :1007-1007
[9]  
Gonzalez-Tejera G, 2010, P R HEALTH SCI J, V29, P299
[10]   Epoxygenase metabolites - Epithelial and vascular actions [J].
Imig, JD .
MOLECULAR BIOTECHNOLOGY, 2000, 16 (03) :233-251